| NCT ID | NCT06355336 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cincinnati Cancer Advisors |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-03-18 |
| Primary Completion | 2034-03-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-03-18 with a primary completion date of 2034-03-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological features, stages, and disease biology. The treatment options are dependent on the disease stage, its features, and the patient's condition and preferences. The disease outcome also varies significantly due to the previous heterogeneity of the features in addition to other social determinants of health. Therefore, it is critical to obtain real-world data that reflects the actual patterns of prostate cancer presentation, work up, management, and outcome. Real World Prostate Cancer Registry (RWPCR) aims at compiling real world data from patients presented with prostate cancer in the tristate area. The data collection will be prospective and longitudinal including patients' demographics and disease characteristics, work up, management, and outcome.
Eligibility Criteria
Inclusion Criteria: All patients with pathologically confirmed primary prostate cancer Diagnosis since January 1st, 2023 Acceptance to sign the consent form 18 years old or older Resident of Ohio, Kentucky or Indiana Exclusion Criteria: Having diagnosis of other cancer except squamous cell cancer of the skin Refusal to sign a consent form.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06355336 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06355336 currently recruiting?
Yes, NCT06355336 is actively recruiting participants. Contact the research team at a.jazieh@cincinnaticanceradvisors.org for enrollment information.
Where is the NCT06355336 trial being conducted?
This trial is being conducted at Cincinnati, United States.
Who is sponsoring the NCT06355336 clinical trial?
NCT06355336 is sponsored by Cincinnati Cancer Advisors. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.